Lacosamide Aristo

Lacosamide, the active ingredient in Lacosamide Aristo, is a anti‑epileptic (sodium channel modulator) presented as an oral tablet for oral use. It is employed to control partial‑onset seizures in patients diagnosed with epilepsy and may be used as adjunct therapy.

GNH USA supplies Lacosamide Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution. Our global logistics network ensures timely delivery to authorized healthcare providers across multiple regions.

Lacosamide is indicated for the treatment of focal epilepsy, specifically targeting partial‑onset seizures. - Partial‑onset seizures: reduces seizure frequency as monotherapy or adjunctive therapy in patients with epilepsy. - Focal seizures in adults: provides seizure control when added to existing antiepileptic regimens. - Refractory focal epilepsy: offers an alternative option for patients who have not responded adequately to other medications.

Lacosamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Nausea: mild to moderate stomach upset. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate pain in the head. - Blurred vision: temporary visual disturbances. - Diplopia: double vision episodes.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Respiratory depression: slowed breathing, especially with concomitant CNS depressants. - Anaphylaxis: acute allergic reaction with hives, swelling, or airway compromise. - Liver injury: elevated transaminases or hepatitis.

When prescribing Lacosamide, clinicians should consider several safety precautions to minimize risk. - Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation or arrhythmias. - Pregnancy: Category B; use only if benefit outweighs potential risk. - Discontinuation: taper gradually to prevent seizure recurrence. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, affecting its plasma levels or increasing adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide concentrations. - Other sodium‑channel blockers (e.g., lamotrigine, oxcarbazepine): can increase risk of CNS depression and dizziness. - QT‑prolonging agents (e.g., erythromycin, fluoroquinolones): may heighten cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): may raise lacosamide levels modestly. - Alcohol: can enhance central nervous system side effects such as drowsiness. - Oral contraceptives: may experience altered hormone levels; monitor efficacy. - Antihypertensives: potential additive blood pressure lowering effect.